UCB, Five Prime Collaborate - Analyst Blog


UCB ( UCBJF ) recently announced a strategic deal with Five Prime Therapeutics, Inc. for the discovery of innovative biologics targets and therapeutics for fibrosis-related inflammatory diseases and central nervous system (CNS) disorders.

As per the agreement, Five Prime will receive roughly $16 million in the form of an upfront fee, technology access fees, research funding and success-based research milestone payments. Additionally, Five Prime could receive exercise fees, product related milestone payments as well as tiered royalties.

UCB and Five Prime will work together to design assays to screen Five Prime's 5600 functional secreted proteins and transmembrane receptor proteins (ligand traps).

Five Prime will use its technology platforms in this collaboration to discover potential drug targets and candidates for fibrosis-related inflammatory diseases and CNS diseases. UCB has the right to license selected protein targets discovered in this program.

This is the second collaboration announced by UCB in the past few weeks. In Feb 2013, UCB entered into an agreement with ConfometRx for the discovery of novel medicines in the neuroscience therapeutic area. This research and development (R&D) collaboration, spanning two years, will harness structural biology to gain insight into G protein coupled receptors (GPCRs) modulation in making drugs.

UCB carries a Zacks Rank #1 (Strong Buy). We expect Cimzia, Vimpat and Neupro to continue performing well in 2013. A few weeks back, Vimpat was approved in the European Union (EU) as a single loading dose option for treating patients suffering from partial onset seizures. Additionally, UCB announced new regulatory filings with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for two additional indications for Cimzia.

Currently, companies like Lannett Company, Inc. ( LCI ), WuXi Pharma Tech (Cayman) Inc. ( WX ) and QLT Inc. ( QLTI ) also carry a Zacks Rank #1.

LANNETT INC (LCI): Free Stock Analysis Report

QLT INC (QLTI): Free Stock Analysis Report

UCB SA (UCBJF): Get Free Report

WUXI PHARMATECH (WX): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

This article appears in: Investing , Business , Stocks

Referenced Stocks: CNS , EU , LCI , QLTI , UCBJF



More from Zacks.com:

Related Videos



Most Active by Volume

  • $47.87 ▲ 10.45%
  • $9.99 ▲ 6.28%
  • $7.92 ▲ 11.24%
  • $59.64 ▲ 0.69%
  • $130.28 ▲ 0.47%
  • $34.01 ▼ 0.64%
  • $11.99 ▼ 8.75%
  • $15.64 ▼ 0.32%
As of 4/24/2015, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com